Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $194.91 USD
Change Today -1.36 / -0.69%
Volume 576.3K
RCPT On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/15 - $203.25
52 Week Low
07/17/14 - $33.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 03/2/15
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $317.0K
Chief Financial Officer
Total Annual Compensation: $386.8K
Chief Medical officer
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.

receptos inc (RCPT) Key Developments

Receptos, Inc.(NasdaqGS:RCPT) added to Russell 1000 Index

Receptos, Inc. has been added to Russell 1000 Index.

Receptos, Inc.(NasdaqGS:RCPT) dropped from Russell 2000 Index

Receptos, Inc. will be removed from Russell 2000 Index

Receptos Reportedly Rejects Takeover Bids

Receptos, Inc. (NasdaqGS:RCPT) has rejected takeover offers from AstraZeneca PLC (LSE:AZN), Gilead Sciences Inc. (NasdaqGS:GILD) and Teva Pharmaceutical Industries Limited (NYSE:TEVA), according to sources. AstraZeneca offered $200 per share while Gilead and Teva offered $280 per share, sources reported. Receptos reportedly rejected offers claiming they undervalued it.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $194.91 USD -1.36

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies

Industry Analysis


Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,342.4x
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,210.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at